Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl.
We studied trihexyphenidyl in the treatment of torsion dystonia in a prospective, double-blind crossover protocol. Thirty-one patients completed the protocol. Twenty-two (71%) had a clinically significant response. After a mean follow-up of 2.4 years, 68% of patients continued to take trihexyphenidyl, and 42% continued to show a considerable or dramatic benefit. The 30-mg dose used was generally well tolerated. High-dosage trihexyphenidyl therapy is effective in the management of torsion dystonia.
D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004422:Dystonia Musculorum Deformans / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009068:Movement / Q000187:drug effects; D011446:Prospective Studies; D011897:Random Allocation; D014282:Trihexyphenidyl / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D014282:Trihexyphenidyl